Oslo, NORWAY and Mountain View, CA USA, Sept 6 2023 - EXACT Therapeutics, a
clinical-stage Norwegian biopharmaceutical precision health company developing
Acoustic Cluster Therapy (ACT®), and Cordance Medical, a leading innovator in
non-invasive opening of the blood-brain barrier (BBB), today announced a
strategic partnership aimed at combining their breakthrough technologies to
revolutionize drug delivery in the treatment of brain diseases.

EXACT Therapeutics' ACT® platform utilizes a unique approach to
ultrasound-mediated, targeted drug enhancement. Their proprietary formulation,
PS101, consists of highly engineered microbubble-microdroplet clusters that can
be co-administered intravenously with a therapeutic agent. The ACT® formulation
is activated by ultrasound, enabling precise targeting of therapeutic
enhancement to the desired location.

Cordance Medical's NeuroAccessTM platform is designed to provide personalized,
targeted opening of the BBB in a non-invasive, painless procedure designed to
take 30 minutes or less. This groundbreaking technology allows the procedure to
be performed in space-constrained environments such as community outpatient
clinics and infusion treatment centers, making it more accessible to patients
worldwide.

This strategic partnership will combine EXACT Therapeutics' ACT® technology and
Cordance Medical's NeuroAccessTM platform, with the aim of delivering more
effective drug therapy across the BBB. By integrating the two technologies,
patients suffering from various brain diseases, including brain tumors and
neurodegenerative disorders, will have access to cutting-edge, targeted
treatment options in upcoming clinical trials.

"Cordance Medical's NeuroAccessTM platform is an ideal complement to our ACT®
technology", said Per Walday, CEO of EXACT Therapeutics. "This partnership
represents a significant milestone in our mission to broaden and enhance the
clinical utility of a wide range of therapeutic agents across various
indications. We are committed to working together to transform the treatment
landscape for patients with brain diseases."

Ryan Dittamore, CEO of Cordance Medical added, "We are excited to partner with
EXACT Therapeutics and leverage their proprietary ACT® technology. Our combined
technologies have the potential to significantly improve drug delivery to the
brain, resulting in better patient outcomes and accessibility to innovative
non-invasive treatments."

About EXACT Therapeutics

EXACT Therapeutics is a clinical-stage Norwegian biopharmaceutical company
specializing in ultrasound-mediated drug delivery. Their proprietary Acoustic
Cluster Therapy (ACT®) platform follows a unique approach to targeted drug
enhancement, with the potential to significantly amplify the clinical utility of
a wide range of therapeutic agents across multiple indications, including
oncology and brain diseases.

About Cordance Medical

Cordance Medical is a leading medical technology company focused on developing
innovative, non-invasive solutions for opening the blood-brain barrier. The
company's flagship product, the NeuroAccess platform, is designed to provide
personalized, targeted treatment in a painless procedure designed to be  30
minutes or less. Cordance Medical is dedicated to improving patient outcomes and
increasing accessibility to advanced medical treatments.

For more information, please contact:
EXACT Therapeutics:
  Per Walday  
  CEO 
  Email: per.walday@exact-tx.com

Cordance Medical:
  Ryan Dittamore
  CEO
  Email: ryan.dittamore@cordancemedical.com